TITLE

Review: Rosiglitazone or pioglitazone as add-on therapy is effective for glycemic control in type 2 diabetes: COMMENTARY

AUTHOR(S)
Home, Philip
PUB. DATE
November 2003
SOURCE
ACP Journal Club;Nov/Dec2003, Vol. 139 Issue 3, p67
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Type 2 diabetes is a progressive condition, which demands a stepped therapeutic approach from lifestyle changes alone, to addition of one or more oral glucose-lowering drugs, to combination with insulin. Peroxisome proliferator-activated receptor-γ agonists, such as rosiglitazone and pioglitazone, have the potential to be true anti-diabetic drugs. These drugs are expensive and it is clear from the review by researchers M. Boucher and colleagues, that they show no advantage in cost-effectiveness over metformin or sulfonylurea monotherapy. Use of these drugs, clinically most effective in people with overt metabolic syndrome, may be an alternative to add-on insulin therapy. Researchers have showed that the introduction of thiazolidinediones can have an important effect on the budget of publicly funded drug programs in Canada.
ACCESSION #
11533501

 

Related Articles

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics